Gregory Fiore

Gregory Fiore

Company: Exacis Biotherapeutics

Job title: Chief Executive Officer


Industry Leader’s Annual Briefing: Reviewing the Innate Killer Landscape, & Setting Industry Goals for 2023 & Beyond 8:30 am

Reflecting on the current advances of the maturing innate immune field, and the changing market and industry dynamics Identifying the current industry focus and upcoming hurdles to development, such as investment, recruitment, trial scale up, and discussing how the industry can work to progress together Considering where NKs, gamma deltas, macrophages, and other innate immune…Read more

day: Day One

Reprogramming iPSCs with mRNA for Footprint- Free, Metabolically Active NK Cell Therapies 9:30 am

Deploying fusogenic lipid delivery systems to deliver mRNA to target cells without endosomal formation or escape Demonstrating full restoration of telomeres and directed differentiation of iPSC cell lines into innate immune cells Discussing the advantage of mRNA platforms for editing, and the use of single base editing for correction to deliver safe, potent cell therapy…Read more

day: Next-Generation Engineering Focus Day
day: Pre-Conference Day AM 1

Panel Discussion: Where are the ‘Low Hanging Fruit’ in RNA-Edited Cell Therapies & What Opportunities are Opening up for the Field? 12:00 pm

Highlighting the priority areas to implement RNA engineering to fill a gap in therapeutic need Gauging the potential impact of RNA editing on therapeutic development Identifying the core hurdles for the innate field to focus on to make RNA engineered cell therapies an enabling technology for global therapeutic accessRead more

day: Next-Generation Engineering Focus Day
day: Pre-Conference Day Track A AM

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.